13 results on '"Brenner, Hermann"'
Search Results
2. Response: Re: Protection From Right- and Left-Sided Colorectal Neoplasms After Colonoscopy: Population-Based Study.
- Author
-
BRENNER, HERMANN, HOFFMEISTER, MICHAEL, ARNDT, VOLKER, and HAUG, ULRIKE
- Subjects
- *
LETTERS to the editor , *COLONOSCOPY , *COLON cancer - Abstract
A response by Hermann Brenner et al, to a letter to the editor about their article "Protection From Right- and Left-Sided Colorectal Neoplasms After Colonoscopy: Population-Based Study" is presented.
- Published
- 2010
- Full Text
- View/download PDF
3. Body Mass Index and Molecular Subtypes of Colorectal Cancer.
- Author
-
Murphy, Neil, Newton, Christina C, Song, Mingyang, Papadimitriou, Nikos, Hoffmeister, Michael, Phipps, Amanda I, Harrison, Tabitha A, Newcomb, Polly A, Aglago, Elom K, Berndt, Sonja I, Brenner, Hermann, Buchanan, Daniel D, Cao, Yin, Chan, Andrew T, Chen, Xuechen, Cheng, Iona, Chang-Claude, Jenny, Dimou, Niki, Drew, David, and Farris, Alton B
- Subjects
- *
BODY mass index , *HEREDITARY nonpolyposis colorectal cancer , *COLORECTAL cancer , *MOLECULAR weights , *BRAF genes , *LOGISTIC regression analysis - Abstract
Background: Obesity is an established risk factor for colorectal cancer (CRC); but the evidence for the association is inconsistent across molecular subtypes of the disease.Methods: We pooled data on BMI, tumor microsatellite instability (MSI) status, CpG island methylator phenotype (CIMP) status, BRAF and KRAS mutations, and Jass classification types for 11,872 CRC cases and 11,013 controls from 11 observational studies. We used multinomial logistic regression to estimate odds ratio (OR) and 95% confidence intervals (CI) adjusted for covariables.Results: Higher BMI was associated with increased CRC risk (OR per 5 kg/m2, 1.18, 95%CI: 1.15-1.22). The positive association was stronger for men than women, but similar across tumor subtypes defined by individual molecular markers. In analyses by Jass type, higher BMI was associated with elevated CRC risk for types 1-4 cases but not for type 5 CRC cases (considered familial-like/Lynch syndrome MSI-H, CIMP-low/negative, BRAF-wildtype, KRAS-wildtype, OR, 1.04, 95%CI: 0.90-1.20). This pattern of associations for BMI and Jass types was consistent by sex and design of contributing studies (cohort or case-control).Conclusions: In contrast to previous reports with fewer study participants, we found limited evidence of heterogeneity for the association between BMI and CRC risk according to molecular subtype, suggesting that obesity influences nearly all major pathways involved in colorectal carcinogenesis. The null association observed for the Jass type 5 suggests that BMI is not a risk factor for the development of CRC for individuals with Lynch syndrome. [ABSTRACT FROM AUTHOR]- Published
- 2023
- Full Text
- View/download PDF
4. Re: Public Knowledge of Benefits of Breast and Prostate Cancer Screening in Europe.
- Author
-
BRENNER, HERMANN, HEYWANG-KÖBRUNNER, SYLVIA, and BECKER, NIKOLAUS
- Subjects
- *
LETTERS to the editor , *PROSTATE cancer - Abstract
A letter to the editor is presented in response to the article "Public Knowledge of Benefits of Breast and Prostate Cancer Screening in Europe," by G. Gigerenzer et al, published in a 2009 issue.
- Published
- 2010
- Full Text
- View/download PDF
5. Distinct Reproductive Risk Profiles for Intrinsic-Like Breast Cancer Subtypes: Pooled Analysis of Population-Based Studies.
- Author
-
Jung, Audrey Y, Ahearn, Thomas U, Behrens, Sabine, Middha, Pooja, Bolla, Manjeet K, Wang, Qin, Arndt, Volker, Aronson, Kristan J, Augustinsson, Annelie, Freeman, Laura E Beane, Becher, Heiko, Brenner, Hermann, Canzian, Federico, Carey, Lisa A, Consortium, CTS, Czene, Kamila, Eliassen, A Heather, Eriksson, Mikael, Evans, D Gareth, and Figueroa, Jonine D
- Subjects
- *
TRIPLE-negative breast cancer , *BREAST cancer , *ETIOLOGY of diseases , *ESTROGEN receptors , *ODDS ratio , *HORMONE receptor positive breast cancer , *PREMATURE menopause - Abstract
Background Reproductive factors have been shown to be differentially associated with risk of estrogen receptor (ER)-positive and ER-negative breast cancer. However, their associations with intrinsic-like subtypes are less clear. Methods Analyses included up to 23 353 cases and 71 072 controls pooled from 31 population-based case-control or cohort studies in the Breast Cancer Association Consortium across 16 countries on 4 continents. Polytomous logistic regression was used to estimate the association between reproductive factors and risk of breast cancer by intrinsic-like subtypes (luminal A-like, luminal B-like, luminal B-HER2–like, HER2-enriched–like, and triple-negative breast cancer) and by invasiveness. All statistical tests were 2-sided. Results Compared with nulliparous women, parous women had a lower risk of luminal A-like, luminal B-like, luminal B-HER2–like, and HER2-enriched–like disease. This association was apparent only after approximately 10 years since last birth and became stronger with increasing time (odds ratio [OR] = 0.59, 95% confidence interval [CI] = 0.49 to 0.71; and OR = 0.36, 95% CI = 0.28 to 0.46 for multiparous women with luminal A-like tumors 20 to less than 25 years after last birth and 45 to less than 50 years after last birth, respectively). In contrast, parous women had a higher risk of triple-negative breast cancer right after their last birth (for multiparous women: OR = 3.12, 95% CI = 2.02 to 4.83) that was attenuated with time but persisted for decades (OR = 1.03, 95% CI = 0.79 to 1.34, for multiparous women 25 to less than 30 years after last birth). Older age at first birth (P heterogeneity <.001 for triple-negative compared with luminal A-like breast cancer) and breastfeeding (P heterogeneity <.001 for triple-negative compared with luminal A-like breast cancer) were associated with lower risk of triple-negative breast cancer but not with other disease subtypes. Younger age at menarche was associated with higher risk of all subtypes; older age at menopause was associated with higher risk of luminal A-like but not triple-negative breast cancer. Associations for in situ tumors were similar to luminal A-like. Conclusions This large and comprehensive study demonstrates a distinct reproductive risk factor profile for triple-negative breast cancer compared with other subtypes, with implications for the understanding of disease etiology and risk prediction. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
6. Risk Stratification for Early-Onset Colorectal Cancer Using a Combination of Genetic and Environmental Risk Scores: An International Multi-Center Study.
- Author
-
Archambault, Alexi N, Jeon, Jihyoun, Lin, Yi, Thomas, Minta, Harrison, Tabitha A, Bishop, D Timothy, Brenner, Hermann, Casey, Graham, Chan, Andrew T, Chang-Claude, Jenny, Figueiredo, Jane C, Gallinger, Steven, Gruber, Stephen B, Gunter, Marc J, Guo, Feng, Hoffmeister, Michael, Jenkins, Mark A, Keku, Temitope O, Marchand, Loïc Le, and Li, Li
- Subjects
- *
RESEARCH , *RESEARCH methodology , *SOCIAL networks , *EARLY detection of cancer , *MEDICAL screening , *EVALUATION research , *COLORECTAL cancer , *RISK assessment , *COMPARATIVE studies , *PSYCHOLOGICAL tests , *DISEASE susceptibility , *RESEARCH funding - Abstract
Background: The incidence of colorectal cancer (CRC) among individuals aged younger than 50 years has been increasing. As screening guidelines lower the recommended age of screening initiation, concerns including the burden on screening capacity and costs have been recognized, suggesting that an individualized approach may be warranted. We developed risk prediction models for early-onset CRC that incorporate an environmental risk score (ERS), including 16 lifestyle and environmental factors, and a polygenic risk score (PRS) of 141 variants.Methods: Relying on risk score weights for ERS and PRS derived from studies of CRC at all ages, we evaluated risks for early-onset CRC in 3486 cases and 3890 controls aged younger than 50 years. Relative and absolute risks for early-onset CRC were assessed according to values of the ERS and PRS. The discriminatory performance of these scores was estimated using the covariate-adjusted area under the receiver operating characteristic curve.Results: Increasing values of ERS and PRS were associated with increasing relative risks for early-onset CRC (odds ratio per SD of ERS = 1.14, 95% confidence interval [CI] = 1.08 to 1.20; odds ratio per SD of PRS = 1.59, 95% CI = 1.51 to 1.68), both contributing to case-control discrimination (area under the curve = 0.631, 95% CI = 0.615 to 0.647). Based on absolute risks, we can expect 26 excess cases per 10 000 men and 21 per 10 000 women among those scoring at the 90th percentile for both risk scores.Conclusions: Personal risk scores have the potential to identify individuals at differential relative and absolute risk for early-onset CRC. Improved discrimination may aid in targeted CRC screening of younger, high-risk individuals, potentially improving outcomes. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
7. Trends in 5- and 10-year Survival After Diagnosis with Childhood Hematologic Malignancies in the United States, 1990-2004.
- Author
-
Pulte, Dianne, Gondos, Adam, and Brenner, Hermann
- Subjects
- *
BLOOD diseases , *JUVENILE diseases , *DIAGNOSIS , *MEDICAL screening - Abstract
Background Advances in the treatment of childhood hematologic malignancies have led to improvements in survival for several of these conditions during the past few decades, but most population-based survival data available to date refer only to patients diagnosed up to the mid-1990s. Methods We used period analysis to assess trends in 5- and 10-year survival in US patients younger than 15 years of age at diagnosis with four hematologic malignancies—acute lymphoblastic leukemia, acute non-lymphoblastic leukemia, Hodgkin lymphoma, and non-Hodgkin lymphoma—over three recent 5-year intervals, 1990-1994, 1995-1999, and 2000-2004, using data on a total of 6957 patients from the Surveillance, Epidemiology, and End Results database. Expected survival for 2005-2009 was estimated by modeling from trends in the preceding intervals. Results Major improvements in 5- and 10-year relative survival between 1990-1994 and 2000-2004 were seen for acute lymphoblastic leukemia (from 80.2% to 87.5% and from 73.4% to 83.8%, respectively), acute non- lymphoblastic leukemia (from 41.9% to 59.9% and from 38.7% to 59.1%, respectively), and non-Hodgkin lymphoma (from 76.6% to 87.7% and from 73.0% to 86.9%, respectively). For those diagnosed with Hodgkin lymphoma, 5- and 10-year survival rates for the 1990-1994 period were 96.1% and 94.4%, respectively, and these rates did not change substantially in the later time periods. Projected 10-year survival rates for children diagnosed in the 2005-2009 period were 88.0% for acute lymphoblastic leukemia, 63.9% for acute non-lymphoblastic leukemia, 90.6% for non-Hodgkin lymphoma, and 94.3% for Hodgkin lymphoma. Conclusions Application of period analysis to a population-based study of childhood hematologic malignancies reveals ongoing increases in survival for three of the four common childhood hematologic malignancies. [ABSTRACT FROM AUTHOR]
- Published
- 2008
- Full Text
- View/download PDF
8. Association of Body Mass Index With Colorectal Cancer Risk by Genome-Wide Variants.
- Author
-
Campbell, Peter T, Lin, Yi, Bien, Stephanie A, Figueiredo, Jane C, Harrison, Tabitha A, Guinter, Mark A, Berndt, Sonja I, Brenner, Hermann, Chan, Andrew T, Chang-Claude, Jenny, Gallinger, Steven J, Gapstur, Susan M, Giles, Graham G, Giovannucci, Edward, Gruber, Stephen B, Gunter, Marc, Hoffmeister, Michael, Jacobs, Eric J, Jenkins, Mark A, and Marchand, Loic Le
- Subjects
- *
BODY mass index , *COLORECTAL cancer , *SINGLE nucleotide polymorphisms , *LOGISTIC regression analysis , *ODDS ratio - Abstract
Background: Body mass index (BMI) is a complex phenotype that may interact with genetic variants to influence colorectal cancer risk.Methods: We tested multiplicative statistical interactions between BMI (per 5 kg/m2) and approximately 2.7 million single nucleotide polymorphisms with colorectal cancer risk among 14 059 colorectal cancer case (53.2% women) and 14 416 control (53.8% women) participants. All analyses were stratified by sex a priori. Statistical methods included 2-step (ie, Cocktail method) and single-step (ie, case-control logistic regression and a joint 2-degree of freedom test) procedures. All statistical tests were two-sided.Results: Each 5 kg/m2 increase in BMI was associated with higher risks of colorectal cancer, less so for women (odds ratio [OR] = 1.14, 95% confidence intervals [CI] = 1.11 to 1.18; P = 9.75 × 10-17) than for men (OR = 1.26, 95% CI = 1.20 to 1.32; P = 2.13 × 10-24). The 2-step Cocktail method identified an interaction for women, but not men, between BMI and a SMAD7 intronic variant at 18q21.1 (rs4939827; Pobserved = .0009; Pthreshold = .005). A joint 2-degree of freedom test was consistent with this finding for women (joint P = 2.43 × 10-10). Each 5 kg/m2 increase in BMI was more strongly associated with colorectal cancer risk for women with the rs4939827-CC genotype (OR = 1.24, 95% CI = 1.16 to 1.32; P = 2.60 × 10-10) than for women with the CT (OR = 1.14, 95% CI = 1.09 to 1.19; P = 1.04 × 10-8) or TT (OR = 1.07, 95% CI = 1.01 to 1.14; P = .02) genotypes.Conclusion: These results provide novel insights on a potential mechanism through which a SMAD7 variant, previously identified as a susceptibility locus for colorectal cancer, and BMI may influence colorectal cancer risk for women. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
9. Genetically Predicted Levels of DNA Methylation Biomarkers and Breast Cancer Risk: Data From 228 951 Women of European Descent.
- Author
-
Yang, Yaohua, Wu, Lang, Shu, Xiao-Ou, Cai, Qiuyin, Shu, Xiang, Li, Bingshan, Guo, Xingyi, Ye, Fei, Michailidou, Kyriaki, Bolla, Manjeet K, Wang, Qin, Dennis, Joe, Andrulis, Irene L, Brenner, Hermann, Chenevix-Trench, Georgia, Campa, Daniele, Castelao, Jose E, Gago-Dominguez, Manuela, Dörk, Thilo, and Hollestelle, Antoinette
- Subjects
- *
DNA methylation , *BREAST cancer , *EPIGENOMICS , *LEUCOCYTES , *METASTATIC breast cancer , *BIOMARKERS , *STATISTICAL power analysis , *BIOLOGICAL models , *RELATIVE medical risk , *RESEARCH , *PREDICTIVE tests , *DNA , *SEQUENCE analysis , *RESEARCH methodology , *CASE-control method , *GENETIC polymorphisms , *EVALUATION research , *MEDICAL cooperation , *COMPARATIVE studies , *DISEASE susceptibility , *GENE expression profiling , *RESEARCH funding , *WHITE people , *STATISTICAL models , *BREAST tumors - Abstract
Background: DNA methylation plays a critical role in breast cancer development. Previous studies have identified DNA methylation marks in white blood cells as promising biomarkers for breast cancer. However, these studies were limited by low statistical power and potential biases. Using a new methodology, we investigated DNA methylation marks for their associations with breast cancer risk.Methods: Statistical models were built to predict levels of DNA methylation marks using genetic data and DNA methylation data from HumanMethylation450 BeadChip from the Framingham Heart Study (n = 1595). The prediction models were validated using data from the Women's Health Initiative (n = 883). We applied these models to genomewide association study (GWAS) data of 122 977 breast cancer patients and 105 974 controls to evaluate if the genetically predicted DNA methylation levels at CpG sites (CpGs) are associated with breast cancer risk. All statistical tests were two-sided.Results: Of the 62 938 CpG sites CpGs investigated, statistically significant associations with breast cancer risk were observed for 450 CpGs at a Bonferroni-corrected threshold of P less than 7.94 × 10-7, including 45 CpGs residing in 18 genomic regions, that have not previously been associated with breast cancer risk. Of the remaining 405 CpGs located within 500 kilobase flaking regions of 70 GWAS-identified breast cancer risk variants, the associations for 11 CpGs were independent of GWAS-identified variants. Integrative analyses of genetic, DNA methylation, and gene expression data found that 38 CpGs may affect breast cancer risk through regulating expression of 21 genes.Conclusion: Our new methodology can identify novel DNA methylation biomarkers for breast cancer risk and can be applied to other diseases. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
10. Association of Aspirin and Nonsteroidal Anti-Inflammatory Drugs With Colorectal Cancer Risk by Molecular Subtypes.
- Author
-
Amitay, Efrat L, Carr, Prudence R, Jansen, Lina, Walter, Viola, Roth, Wilfried, Herpel, Esther, Kloor, Matthias, Bläker, Hendrik, Chang-Claude, Jenny, Brenner, Hermann, and Hoffmeister, Michael
- Subjects
- *
GENETIC mutation , *ANTI-inflammatory agents , *COLORECTAL cancer , *ASPIRIN , *POPULATION-based case control , *HEREDITARY nonpolyposis colorectal cancer , *MOLECULAR association - Abstract
Background: Regular use of aspirin and nonsteroidal anti-inflammatory drugs (NSAIDs) for a longer period has been inversely associated with colorectal cancer (CRC) risk. However, CRC is a heterogenic disease, and little is known regarding the associations with molecular pathological subtypes.Methods: Analyses included 2444 cases with a first diagnosis of CRC and 3130 healthy controls from a German population-based case control study. Tumor tissue samples were analyzed for major molecular pathological features: microsatellite instability (MSI), CpG island methylator phenotype, B-Raf proto-oncogene serine/threonine kinase (BRAF) mutation, and Kirsten rat sarcoma viral oncogene homolog gene (KRAS) mutation. Information on past and current use of NSAIDs, including aspirin, was obtained by standardized interviews. Multinomial logistic regression models were used to calculate adjusted odds ratios (ORs) and 95% confidence intervals (CIs). All statistical tests were two-sided.Results: Regular use of NSAIDs was associated with a reduced CRC risk if tumors were MSS (OR = 0.66, 95% CI = 0.57 to 0.77), BRAF wildtype (OR = 0.67, 95% CI = 0.58 to 0.78), or KRAS wildtype (OR = 0.68, 95% CI = 0.58 to 0.80). Regular NSAID use was less clearly and mostly not statistically significantly associated with CRC risk reduction for MSI-high, BRAF-mutated, or KRAS-mutated CRC. In more specific analyses on MSI-high CRC, regular use of NSAIDs was associated with much stronger risk reduction in the absence of BRAF or KRAS mutations (OR = 0.34, 95% CI = 0.18 to 0.65) but not with KRAS- or BRAF-mutated MSI-high CRC (Pheterogeneity < .001). Results for just aspirin use were similar.Conclusion: Our study suggests variation in risk reduction of CRC subtypes following regular use of NSAIDs and aspirin. Regular use of NSAIDs and aspirin may be more strongly associated with risk reduction of MSI-high CRC without KRAS or BRAF mutation. [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
11. Burden of Cancer in a Large Consortium of Prospective Cohorts in Europe.
- Author
-
Tsilidis, Konstantinos K., Papadimitriou, Nikos, Capothanassi, Despoina, Bamia, Christina, Benetou, Vassiliki, Jenab, Mazda, Heinz Freisling, Frank Kee, Nelen, Annemarie, O'Doherty, Mark G., Scott, Angela, Soerjomataram, Isabelle, Tjønneland, Anne, May, Anne M., Quiros, J. Ramon, Pettersson-Kymmer, Ulrika, Brenner, Hermann, Schöttker, Ben, Mathiesen, Ellisiv Bøgeberg, and Njølstad, Inger
- Subjects
- *
CANCER risk factors , *DISABILITIES , *EARLY death , *HEALTH of older people , *COHORT analysis , *SURVIVAL analysis (Biometry) , *ADIPOSE tissues , *HUMAN body composition , *ALCOHOL drinking , *LIFE expectancy , *LONGITUDINAL method , *TYPE 2 diabetes , *SMOKING , *TUMORS , *QUALITY-adjusted life years , *SEDENTARY lifestyles - Abstract
Background: Disability-adjusted life-years (DALYs) are an indicator of mortality, morbidity, and disability. We calculated DALYs for cancer in middle-aged and older adults participating in the Consortium on Health and Ageing Network of Cohorts in Europe and the United States (CHANCES) consortium.Methods: A total of 90 199 participants from five European cohorts with 10 455 incident cancers and 4399 deaths were included in this study. DALYs were calculated as the sum of the years of life lost because of premature mortality (YLLs) and the years lost because of disability (YLDs). Population-attributable fractions (PAFs) were also estimated for five cancer risk factors, ie, smoking, adiposity, physical inactivity, alcohol intake, and type II diabetes.Results: After a median follow-up of 12 years, the total number of DALYs lost from cancer was 34 474 (382 per 1000 individuals) with a similar distribution by sex. Lung cancer was responsible for the largest number of lost DALYs (22.9%), followed by colorectal (15.3%), prostate (10.2%), and breast cancer (8.7%). Mortality (81.6% of DALYs) predominated over disability. Ever cigarette smoking was the risk factor responsible for the greatest total cancer burden (24.0%, 95% confidence interval [CI] = 22.2% to 26.0%), followed by physical inactivity (4.9%, 95% CI = 0.8% to 8.1%) and adiposity (1.8%, 95% CI = 0.2% to 2.8%).Conclusions: DALYs lost from cancer were substantial in this large European sample of middle-aged and older adults. Even if the burden of disease because of cancer is predominantly caused by mortality, some cancers have sizeable consequences for disability. Smoking remained the predominant risk factor for total cancer burden. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
12. Statin Use and Survival After Colorectal Cancer: The Importance of Comprehensive Confounder Adjustment.
- Author
-
Hoffmeister, Michael, Jansen, Lina, Rudolph, Anja, Toth, Csaba, Kloor, Matthias, Roth, Wilfried, Bläker, Hendrik, Chang-Claude, Jenny, and Brenner, Hermann
- Subjects
- *
STATINS (Cardiovascular agents) , *COLON cancer patients , *COLON cancer diagnosis , *REGRESSION analysis - Abstract
Background: Statins have been associated with moderate reductions in mortality among colorectal cancer (CRC) patients, but these studies lacked adjustment for some potentially relevant factors associated with statin use. We aimed to provide more detailed results on this association from a population-based patient cohort study. Methods: Use of statins and other risk or protective factors were assessed in standardized interviews with 2697 patients from southern Germany with a diagnosis of incident CRC between 2003 and 2009 (Darmkrebs: Chancen der Verhütung durch Screening [DACHS] study). Follow-up included assessment of therapy details, recurrence, vital status, and cause of death. Information about molecular pathological subtypes of CRC was available for 1209 patients. Cox proportional hazard regression models were used to estimate adjusted hazard ratios (HRs) and their 95% confidence intervals (CIs). All statistical tests were two-sided. Results: Patients were age 68 years on average, 412 used statins (15%), and 769 died during follow-up (29%). After a median follow-up time of 3.4 years, use of statins was not associated with overall (HR = 1.10, 95% CI = 0.85 to 1.41), CRC-specific (HR = 1.11, 95% CI = 0.82 to 1.50), or recurrence-free survival (HR = 0.90, 95% CI = 0.63 to 1.27). Analyses in relevant subgroups also showed no association of statin use with overall and CRC-specific survival, and no associations were observed after stratifying for major pathological subtypes. Among stage I and II patients, statin use was associated with better recurrencefree but not with better CRC-specific survival. Conclusions: Statin use was not associated with reduced mortality among CRC patients. Effects reported in previous studies might reflect incomplete control for stage at diagnosis and other factors associated with the use of statins. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
13. Statin use and survival after colorectal cancer: the importance of comprehensive confounder adjustment.
- Author
-
Hoffmeister, Michael, Jansen, Lina, Rudolph, Anja, Toth, Csaba, Kloor, Matthias, Roth, Wilfried, Bläker, Hendrik, Chang-Claude, Jenny, and Brenner, Hermann
- Published
- 2015
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.